Avadel Pharmaceuticals to Provide a Company Update and Report Fourth Quarter and Full Year 2020 Financial Results, on March 9th

DUBLIN, Ireland, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate designed to treat excessive daytime sleepiness and cataplexy in patients with narcolepsy, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Tuesday, March 9, 2021, to provide a company update and discuss the Company's financial results for the fourth quarter and full year ended December 31, 2020.

To access the conference call, investors are invited to dial [phone] (U.S. and Canada) or [phone] (International). The conference ID number is 13716363. A live audio webcast can be accessed by visiting the investor relations section of the Company’s website, www.avadel.com. A replay of the webcast will be archived on Avadel’s website for 90 days following the event.

Contacts:

Investor Contacts
Tom McHugh
Chief Financial Officer
Phone: [phone]
Email: [e-mail]

Tim McCarthy
LifeSci Advisors, LLC
Phone: [phone]
Email: [e-mail]

Media Contact
Patrick Bursey
LifeSci Communications, LLC
Phone: [phone]
Email: [e-mail]